Pivotal Study Okayed for Nephropathy Prevention Device

Share this content:

PLC Systems Inc., of Franklin, Mass., has received conditional approval to begin enrollment in a pivotal trial to study the effectiveness of its RenalGuard Therapy and RenalGuard System in the prevention of contrast-induced nephropathy (CIN).


RenalGuard is an automated fluid-replacement device intended for interventional cardiology and radiology patients undergoing imaging procedures, based on clinical data that suggest that a high urine output during imaging allows for rapid elimination of toxins in contrast media, reducing their harmful effects.


Older patients, diabetics, and patients with pre-existing renal impairment are at elevated risk for CIN when undergoing interventional procedures requiring radiographic contrast media. Enrollment in the pivotal study is expected to last through 2009.

You must be a registered member of Renal and Urology News to post a comment.